64% YoY growth, capacity on track despite FDC delays
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade B
Hit 11,000 MTPA capacity by March 2026 as guided. FDC timeline slipped from FY27 end to FY28-29 (6-month delay); now phased. Core growth narrative intact.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Vintage delivered a strong quarter with 64.4% YoY revenue and 57.3% PAT growth on 100% capacity utilization, corroborating multi-year 80-85% growth guidance when freeze-dried capacity ramps in FY28-29. Long-term thesis intact: 5,500 MTPA freeze-dried (higher margin by 2-3%) with 100% customer pre-commitments. Near-term risk: FDC delayed to Sept 2027 (from prior June-July target) and funding structure under review, but not a deal-breaker.
₹223 Cr
Revenue · +64.4% YoY₹28.1 Cr
Reported PAT · +57.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue increased 64.4% YoY with strong volume growth
METQ2 revenue ₹222.97 Cr vs prior year. Growth from volume growth not higher realization.
Achieved 100% utilization of 11,000 MTPA spray-dried capacity
METProduction 2,737 MTPA Q2 annualizes to ~10,950 MTPA; ~95% utilization confirmed for spray-dried.
16,500 MTPA by end of FY27; freeze-dried expansion on track
MISSFDC Phase 1 (5,500 MTPA) now coming in Sept 2027 onwards (H2 FY28), Phase 2 in Sept 2029. Delayed from prior FY27 end target.
100% of freeze-dried capacity pre-booked by customers
METReceived commitments from buyers, 'almost 100%' letters of intent; visibility intact.
Earnings quality
What changed since the last call
FDC timeline extended
DowngradePrior guidance 16,500 MTPA 'by end of FY27'; now FDC phases in FY28-FY29 (Sept onwards). 6-month push due to ESG compliance from European bank.
Funding structure under review
DowngradeInitially no equity planned; now exploring 'small equity dilution' for FDC ₹550 Cr capex due to negative pledge clause on foreign loans. Board approved ₹325 Cr fundraise (yet to decide on structure).
Capacity utilization maintained
Neutral100% utilization of 11,000 MTPA spray-dried on track; mix shift to agglomerated (higher margin) ongoing. No change vs prior.
B2C strategy timing pushed
DowngradePrior may have implied earlier B2C entry; now clarity that B2C enters from FY30 onwards (after FDC stabilizes and cash flows improve).
The Q&A
Analysts probed execution risk on FDC delays, capex overruns, margin trajectory, customer concentration, and fundraising. Management held firm on customer commitments (100% intent received), timeline clarity (Phase 1 Sept 2027 onwards, Phase 2 Sept 2029), and margin improvement (2-3% when FDC online). Some hedging on B2C and fundraising (exploring options) but overall confident tone.
Capacity & utilization — Gaurav Shukla, Finvesters
AnsweredGrowth is volume-driven, not realization. 100% utilization of 11,000 MTPA now at ~95% spray-dried, continuing this.
FDC capex & ROCE — Jatin Damania, SVAN Investments
Answered₹550 Cr total capex, ₹220 Cr spent. Phase 1 (5.5k) H2 FY28, Phase 2 Sept 2029. 70% utilization first year. ~70% utilization expected, ROCE similar to existing 11k plant. Margin uplift 2-3% in FY29.
B2C entry & market opportunity — Umesh Gupta, AlphaOptimus PMS
AnsweredB2C strategy from FY30 onwards, not until FDC online and cash flows improve. Focus remains B2B now; B2C when FDC comes online as product enabler.
Land & facility expansion — Omkar Gugardare, Shree Investments
Answered22 acres acquired; will support up to 16,500 MTPA. Next phase (5.5k freeze-dried Phase 2) coming in ~12 months post Phase 1. Capex for Phase 2 ~₹350 Cr, mostly brownfield.
Fundraising & equity dilution — Ishan Modi, Individual Investor
PartialForeign loans have negative pledge clause, making it difficult to get Indian bank loans. Exploring small equity dilution as alternative, still evaluating options. May not need dilution if alternatives materialize.
Revenue mix & realization — Despali Bansal, Ventura Enterprises
AnsweredQ2 production 2,737 MTPA, sales 2,581 MTPA. 85% domestic (small packs), 15% export. Chicory capacity maxed; ~5% volume increase limited by crop shortage.
Margin trajectory & inputs — Omkar Gugardare, Shree Investments
AnsweredAgglomerated ~2% higher margin than spray. Freeze-dried 3-4% higher margin than agglomeration. At 100% capacity utilization, margins should improve 3-4% incrementally from FDC.
Coffee input sourcing & pricing — Tanmay, Individual Investor
Answered65-70% from India, 30-35% Uganda/Indonesia. Coffee prices expected to remain stable; no significant increase anticipated. Geopolitical impact on logistics main concern.
FDC delay & impact — Janav Shah, Individual Investor
AnsweredDelay due to ESG compliance from European bank (negative pledge). Building/civil ready by FY29; only equipment install needed. Phase 1 commercial ops from Sept 2027, H2 FY28 benefit realization.
FDC pre-bookings — Omkar Gugardare, Shree Investments
AnsweredReceived 100% letters of intent from customers (Europe, US, Russia, SE Asia). Commitments intact. Some new markets still untapped (South Korea, Japan).
On-ground execution — Prabhat Agarwal, Finvesters
PartialOnline segment currently small, operating under franchisee model. Not focus yet. Clarity on growth to come in next couple months after appointing distributor.
Margin sustainability — Meet Mehta, Entegrity Ventures
AnsweredVolume growth 40%, value growth 60-65% due to higher realization (agglomerated mix shift, chicory price rise). Coffee prices stable; no major input inflation foreseen.
Guidance
FY28-FY29: 80-85% growth from freeze-dried ramp
HighAssumes FDC Phase 1 (5.5k MTPA) at ~70% utilization from Sept 2027 onwards and full utilization of 11k MTPA existing. Customer commitments (100% letters of intent) underpin confidence.
FY27: ~10,500 MTPA visibility on spray-dried, 5-10% QoQ growth in Q3-Q4
High100% capacity utilization being achieved; Q3-Q4 are slower seasonal quarters but expected to continue strong growth.
FY27 margins to remain similar, slight improvement
MediumTAX rate to normalize to 25% from current 26.1%; operating leverage from capacity. Product mix shift supports; chicory headwinds moderate gains.
FY29: 2-3% margin improvement when FDC produces 6-7 months
MediumFreeze-dried margins 3-4% higher than agglomerated. Assumes 70% utilization in H1 and ramp to higher levels in H2 FY29.
FDC total capex ₹550 Cr; ₹220 Cr already spent, ₹150 Cr more in FY27
HighPhase 1 (5.5k MTPA) brownfield project at TGHC park. Equipment sourcing ongoing from Europe and other countries.
Phase 2 (5.5k MTPA) FY28-FY29: ~₹350 Cr additional capex
MediumTimeline Sept 2029 for commercial ops. Capex expected in FY28-FY29; decision in Q1 FY28 on structure (debt/equity/hybrid).
Risks the call surfaced
FDC execution
HighFDC Phase 1 delayed June-July to Aug-Sept (6 months). Full capacity 16,500 MTPA pushed from FY27 to FY28-FY29. Capex ₹550 Cr (Phase 1) + ₹350 Cr (Phase 2) at risk from supply chain, ESG compliance.
Geopolitical logistics
MediumExport-oriented company (growing segment); geopolitical tensions affecting container availability and shipping costs. Passed on to customers but margin risk if demand softens.
Input sourcing concentration
Medium65-70% sourcing from India, 30-35% from Uganda/Indonesia. Single-origin crop failures could spike input costs. India drought, Uganda/Uganda supply shock would hit margins.
Funding structure
MediumForeign bank loans contain negative pledge clause restricting Indian bank borrowing. Equity dilution being explored for FDC capex (₹550 Cr Phase 1). Board approved ₹325 Cr fundraise; structure TBD.
Customer concentration
Low100% of FDC capacity (5.5k MTPA) pre-committed via letters of intent to existing customers. Limited room for new customer onboarding or higher-price markets. Export concentration in few regions.
Management
Score 8/10. Clear and candid. Management articulated strategy (B2B → freeze-dried → B2C) transparently. Acknowledged delays (FDC) and funding challenges without evasion. Detailed capex, customer commitments, and capacity roadmap. Some hedging on B2C and online revenue timing, but justified. Strong on capacity ramp (11,000 MTPA by March 2026 as guided). FDC timeline slipped 6 months (June-July to Aug-Sept) due to ESG compliance; not management fault. Operational metrics (100% utilization, 64% YoY growth) exceeded prior expectations. Cash generation positive (₹51.16 Cr H1).
1 · H2 FY28
FDC Phase 1 (5.5k MTPA) trial production Aug-Sept, commercial Sept onwards
2 · Q1 Q2 FY28
Full capacity utilization at 11,000 MTPA spray-dried; expect 5-10% YoY growth
3 · FY29
FDC ramps to ~70% utilization, margin uplift 2-3% starts showing
Near-term risk: FDC delayed to Sept 2027 (from prior June-July target) and funding structure under review, but not a deal-breaker.
Vintage Coffee Q2 FY27: PAT +35% QoQ to ₹28.1 Cr; margins dip, YoY distorted by merger
PAT +57.34% YoY · revenue +64.42% · margins compressing
₹222.97 Cr
+64.42% YoY
₹28.06 Cr
+57.34% YoY
12.49%
₹1.92
Vintage Coffee and Beverages' consolidated Q2 FY27 (quarter ended September 30, 2026) revenue came in at ₹222.97 Cr and PAT at ₹28.06 Cr (EPS ₹1.92), up 38.5% and 35.0% respectively over the restated Q1 FY27 base (₹161.00 Cr / ₹20.79 Cr) — a genuine like-for-like comparison, since Q1 FY27 was itself restated to include Vintage Coffee Private Limited and Delecto Foods Private Limited, which amalgamated into the listed entity effective October 1, 2025 under an NCLT-sanctioned scheme (order dated 21 July 2026, filed with the RoC 31 August 2026). The year-ago quarter (Sept 2025, PAT ₹17.83 Cr) was NOT restated for the merger, so the headline YoY prints of +64.4% revenue and +57.3% PAT reflect a change in consolidation scope rather than organic growth — the company and its auditors explicitly flag the two periods as not comparable (Note 2 / Emphasis of Matter), and that caveat should travel with any YoY figure quoted from this result. No sell-side consensus for this specific quarter turned up in search; Nuvama's prior 'buy' initiation (₹250 target) is the only identified coverage and carries no published Q2 estimate, so vsStreet is unknown rather than a beat or miss.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
Margins eased sequentially even as volumes scaled: NPM slipped to 12.49% from 12.79% in Q1 FY27, and OPM to 18.91% from 19.62%, as depreciation (+22.4% QoQ to ₹3.45 Cr) and employee costs (+26.8% QoQ to ₹4.44 Cr) outran the 38.5% revenue growth — consistent with a business mid-ramp on new capacity rather than a cost blowout. The effective tax rate was 26.1% (₹9.91 Cr tax on ₹37.97 Cr PBT), tracking close to management's guided 'full 25% rate from Q4 FY26.' H1 FY27 operating cash flow turned positive at ₹51.16 Cr against an outflow of ₹23.96 Cr in H1 FY26 — in line with the prior concall's guidance for FY26 breakeven operating cash flow and positive generation thereafter.
The stock went into the print at ₹163.85, down 10.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management guides for significant capacity growth, increasing total capacity to 11,000 MTPA by March 2026 and 16,500 MTPA by the end of FY27 with the addition of a high-margin freeze-dried coffee plant. They expect full utilization of the new spray-dried capacity in Q1 FY27 and 65-70% utilization of the freeze-dried fa
— This quarter: met
Capex matches the guided build-out: PPE and CWIP additions totalled ₹99.35 Cr in H1 FY27 (vs ₹34.89 Cr in H1 FY26), lifting CWIP to ₹130.16 Cr as of September 30, pointing toward management's stated targets of 11,000 MTPA capacity by March 2026 and 16,500 MTPA by end-FY27, including the new freeze-dried coffee line guided for 65-70% first-year utilization — this filing carries no production-volume disclosure, so utilization itself isn't verifiable from the P&L alone. Around the print, the board raised the borrowing limit to ₹1,000 Cr (October 20) to fund the capex, and promoters (including Chin Corp and Mohit Rathi & PACs) released pledged shares worth roughly ₹7.5 Cr and 4.18 Cr shares respectively (October 9) — a reduction in promoter-collateral risk heading into a debt-funded expansion phase. Post-amalgamation, the company also confirmed it now has no subsidiaries, meaning standalone and consolidated results are effectively identical going forward.
W1
Freeze-dried coffee plant utilization, guided at 65-70% in its first year — watch for the ramp showing up in revenue mix/realization over the next 1-2 quarters
W2
Effective tax rate trajectory toward management's guided 'full 25% from Q4 FY26' (currently 26.1% in Q2 FY27)
W3
CWIP (₹130.16 Cr as of Sep 30, 2026) converting into operating PPE as capacity scales to the guided 16,500 MTPA by end-FY27, and its drag on depreciation/margins
Figures in source are ₹ Lakh (confirmed against DB: Q1 FY27 restated revenue 16,099.78 Lakh = ₹160.998 Cr matches prior-quarter record exactly); only one P&L statement is presented (shows Equity-holders-of-Parent/NCI lines, mapped to consolidated per hard rule) — standalone left null, and per Note 2 the company now has no subsidiaries post-amalgamation so the two bases are effectively identical; Note 2/auditor Emphasis of Matter flags the year-ago (Sep-2025) column as NOT restated for the Vintage Coffee Pvt Ltd/Delecto Foods Pvt Ltd amalgamation (appointed date 1-Oct-2025), so YoY is not like-for-like while QoQ (vs restated Q1 FY27) is comparable; tax figures computed as Current Tax + Deferred Tax per bracket signs, verified against PBT-PAT.
Strong Organic Delivery, But the Catalyst Is Delayed
Vintage delivered 64% YoY revenue growth on 100% capacity utilization — real numbers, no one-time gains. But the marquee catalyst (freeze-dried coffee plant) is pushed back 6 months, and the market has marked the stock down 18% from its all-time high on execution concerns.
₹28.1 Cr
+57.3% YoY
18.9%
+244 bps YoY
100%
11,000 MTPA spray-dried
Vintage Coffee delivered a genuinely strong organic quarter — 64% revenue growth on 100% utilization of the 11,000 MTPA spray-dried plant, with EBITDA margin expanding 244 basis points to 18.9%. No MTM gains, no tax anomalies, no inventory revaluations. The delivered profit is the organic one. And yet the stock has fallen 18% from its all-time high of ₹191.22. The gap between the operational story and the market's reaction is the tension of the quarter.
Where the growth came from
Revenue ₹223 Cr is volume-driven, not realization uplift. Q2 production came in at 2,737 MTPA, annualizing to ~10,950 MTPA — roughly 95% of the installed 11,000 MTPA capacity for spray-dried. The company has shifted product mix toward agglomerated coffee (55% of sales vs. 45% spray), which carries 2% higher margins, and this mix benefit is real and sustainable, not a one-time from chicory pricing or commodity tailwinds. Chicory production is capped — capacity is fully utilized — so volume growth there is limited to ~5% by crop constraints, not market demand. In short, the 64% top-line growth is the result of running a maxed-out plant and upgrading the product into higher-margin formats.
Revenue up 64.4% YoY with strong volume growth
SupportedQ2 production 2,737 MTPA annualizes to ~10,950 MTPA (95% of 11k capacity). Sales ₹223 Cr. Growth is volume, not pricing.
Achieved 100% utilization of 11,000 MTPA spray-dried capacity
SupportedProduction 2,737 MTPA Q2 annualizes to ~10,950 MTPA, confirming ~95% sustained utilization. Plant is maxed.
16,500 MTPA by end of FY27; freeze-dried on track
ContradictedFDC Phase 1 (5,500 MTPA) now coming Sept 2027 onwards (originally June-July), pushed 6 months. Phase 2 Sept 2029. Full 16,500 MTPA is now FY28–FY29, not FY27.
100% of freeze-dried capacity pre-booked by customers
SupportedReceived letters of intent covering 100% of Phase 1 from buyers in Europe, US, Russia, SE Asia. Commitments are in writing.
What changed on this call
FDC timeline: June-July 2027 → Aug-Sept 2027 (6-month delay due to ESG compliance from European bank lender)
Full capacity target: 16,500 MTPA 'by end of FY27' → now FY28–FY29 with phased ramp
Funding strategy: Initially no equity planned → now exploring 'small equity dilution' for ₹550 Cr FDC capex due to negative pledge clause on foreign loans
B2C entry: Previously vague timing → now clarity: FY30 onwards (after FDC stabilizes and cash flows improve)
None of these are dealbreakers individually. The FDC timeline slip is a communications miss — management should have flagged 'the project was always designed to come online in H2 FY28, not FY27' more explicitly upfront. The funding being finalized (equity dilution being explored) suggests some tightness but the board approved ₹325 Cr fundraising and OCF is positive (₹51.16 Cr in H1), so there are multiple funding knobs to pull. What they do signal collectively is that the long-term thesis — 80-85% growth in FY28–FY29 when FDC ramps — is credible but now hinges on execution on a compressed, revised timeline.
Earnings quality: What normalizes next
Tax rate came in at 26.1% vs. the 25% expected full rate from Q4 FY26 onwards. This is normalizing but not there yet; expect a ₹0.3–0.4 Cr tailwind when it hits 25%. Gross margin of 27.6% (+293 bps YoY) is strong but moderated 133 bps QoQ — the chicory price uplift (4-5% due to crop scarcity) is a one-off benefit that will reverse if the crop recovers, and coffee input costs remain stable. The product mix shift to agglomerated is the real, repeatable driver of margin expansion. So adjusted PAT is approximately ₹28.1 Cr as reported (no one-time items to strip out), and the margin track record (244 bps EBITDA expansion YoY) is operational leverage, not a mirage.
FDC execution delay and capex overrun
HighPhase 1 already pushed 6 months (June-July to Aug-Sept 2027). ₹550 Cr capex is at risk from equipment sourcing, ESG compliance, installation delays. Any further slip would push off the 80-85% FY28–FY29 growth guidance. This is the marquee catalyst.
Geopolitical logistics and export margins
Medium15% of revenue from exports (Europe, US, Russia, SE Asia). Container availability and shipping costs are headwinds. If demand softens, export margins could compress faster than domestic. Passed on to customers but margin risk if pricing power erodes.
Funding structure and equity dilution
MediumBoard approved ₹325 Cr fundraise for FDC capex; structure TBD. Foreign bank loans have negative pledge clause, limiting leverage options. If dilution is >5-10%, near-term EPS accretion muted. Execution risk on finalizing funding by the time FDC construction ramps.
Customer concentration on FDC pre-books
Low100% of Phase 1 (5,500 MTPA) pre-booked to existing customers. Limits upside optionality if a new, higher-price market opens. But commitments are in writing; customer risk is lower. Phase 2 has more flexibility.
How the street is positioned
The stock is trading at ₹156.28, down 18% from its all-time high of ₹191.22. It's below the 20-day average (₹160.73) and the 50-day average (₹171.05) but above the 200-day average (₹151.91), signaling a downtrend with emerging support. Over the past 52 weeks, the stock has ranged from ₹120.24 to ₹191.22; today's price sits 30% above the low and 18% below the high. RSI is 44.6, neutral, leaving room for movement in either direction.
Institutional flows are net long: FII holding increased 55 basis points to 5.38% QoQ, while DII increased 196 basis points to 9.59%. Both are nibbling higher despite the 18% drawdown — a signal that big money sees value at current levels. Volume trend is increasing, which could indicate accumulation. Bulk deals in the past six months show no promoter selling near the highs; the only meaningful activity was HRTI buying 9.2 lakh shares at ₹184.97 and selling 6.6 lakh the same day in Aug (a short-term trade, not strategic positioning).
The market's own verdict: The 18% drawdown from ATH despite 64% organic revenue growth and 244 bps margin expansion reflects skepticism about the FDC catalyst and execution risk. The increases in FII and DII, combined with rising volume, suggest some institutions are buying the dip — interpreting the drawdown as an overreaction to the timeline slip, not a fundamental break. The honest reading: the market has priced in the FDC delay and some execution risk, and is now hunting for entry points on the conviction that the long-term thesis (80-85% growth in FY28–FY29) remains intact if management stays on the new schedule.
The debate
Bulls say: Vintage has proven operational chops (11k MTPA on time, now 100% utilized). 64% organic growth with margin expansion is real. The 5,500 MTPA FDC is a concrete cash driver with 100% customer pre-commitments locked in. 80-85% guidance for FY28–FY29 is achievable if FDC starts on the new Sept 2027 timeline. The 18% drawdown is a gift for long-term holders.
Bears counter: FDC is delayed 6 months and hasn't started yet. Freeze-dried is new for Vintage; execution risk is real. Funding is still being finalized (equity dilution possible). Geopolitical logistics (container scarcity, shipping costs) are headwinds on the 15% export revenue. If FDC delays push past Sept 2027, or if any of these execution risks bite, the 80-85% guidance is toast.
The honest read: Vintage delivered exactly what was promised on the spray-dried story — 100% utilization at 11k MTPA, margin expansion from mix shift, 64% organic growth. Management is credible on delivering, as evidenced by hitting the 11k capacity milestone by March 2026 as guided. The FDC delay is a 6-month push, not a year, and it's blamed on ESG compliance from a European bank, not operational chaos. The long-term thesis (80-85% growth in FY28–FY29, 2-3% margin uplift) is still on the table if management holds the Sept 2027 timeline and executes the funding raise without massive dilution. The 18% drawdown has likely priced in the delay and some execution risk; the real test is whether FDC starts on schedule in H2 FY28 and whether customer demand materializes as the 100% pre-bookings suggest. If both hold, the stock has room to run. If either slips, bears have a point.
1 · Q1 Q2 FY28: Spray-dried ramp endgame
Management guided 5-10% QoQ growth in Q3–Q4 FY27 (seasonal slower quarters), with continued 100% utilization of 11k MTPA expected. Watch for delivery on this and any margin expansion updates. This is the 'show me' quarter on whether management can sustain near-term delivery while FDC is being built.
2 · H2 FY28: FDC Phase 1 trial production and commercial ramp
The Aug-Sept 2027 trial production timeline is the linchpin. Any delay here would push back the commercial ramp and the 80-85% FY28–FY29 growth thesis. Watch for management commentary on trial production progress, equipment delivery, customer takeoff, and any further timeline adjustments.
3 · FY29: FDC utilization ramp and margin uplift realization
Management guided for ~70% utilization of the 5,500 MTPA FDC in its first year (FY28) and a 2-3% margin uplift from the higher-margin freeze-dried product when it ramps. FY29 is when the margin story materializes. Watch for utilization, customer delivery, and margin realization against the 2-3% target.
Vintage delivered a strong organic quarter — 64% revenue growth on 100% utilization, 244 bps EBITDA margin expansion, and real volume-driven topline growth. No one-time items, no quality concerns. The operational story is solid and proven.
The market has marked the stock down 18% from its all-time high on concerns about FDC execution delays (6 months already pushed, still not started) and funding uncertainty (equity dilution being explored). These are real risks, not noise.
The long-term thesis — 80-85% growth in FY28–FY29 when the 5,500 MTPA freeze-dried plant ramps with 100% customer pre-commitments — remains credible if management holds the new Sept 2027 timeline and executes the funding raise without massive dilution. Management's track record (11k MTPA on time) suggests it can deliver.
Vintage is a steady-state compounder today (100% capacity utilization, mix shift to higher-margin products). The FDC ramp is a step-change catalyst that's been delayed 6 months but not derailed. The 18% drawdown has priced in the delay and execution risk. If FDC starts on schedule and customer demand holds, the stock has room to run. If delays extend or execution stumbles, the 80-85% guidance is at risk.
The number to track from here: FDC Phase 1 trial production timeline. If it stays on track for Aug-Sept 2027 with commercial ramp from Sept onwards, the 18% markdown is an opportunity. If it slips further, the bears have a point.